IBD Rating Upgrades: Legend Biotech Corp Shows Improved Technical Strength

Legend Biotech Corp (LEGN) saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 65 to 76.


When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

IBD’s proprietary rating tracks price action with a 1 (worst) to 99 (best) score. The grade shows how a stock’s price movement over the last 52 weeks stacks up against all the other stocks in our database.

History reveals that the top-performing stocks tend to have an RS Rating of above 80 as they launch their largest price moves. See if Legend Biotech Corp can continue to show renewed price strength and hit that benchmark.

Looking For The Best Stocks To Buy And Watch? Start Here

While Legend Biotech Corp is not near an ideal buying range right now, see if it manages to form and break out from a proper base.

Earnings growth fell in the company’s most recent report from 0% to -57%, but the top line rose from 18% to 74%.

Legend Biotech Corp holds the No. 166 rank among its peers in the Medical-Biomed/Biotech industry group. Biontech Se Ads (BNTX) and Alkermes (ALKS) are also among the group’s highest-rated stocks.


Biotech And Pharmaceutical Industry And Stock News

Stocks With Rising Relative Strength Ratings

Why Should You Use IBD’s Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

Find Top Stocks Near A Buy Point With IBD Leaderboard

Most Related Links :
editorpen Governmental News Finance News

Source link

Back to top button